The Cellular Pathology Department provides Solihull Dermatology Department with a trained Specialist Biomedical Scientist and a Consultant Histopathologist to enable microscopic examination and rapid diagnosis during the skin surgery.
The Mohs frozen section procedure is used for the examination of unfixed skin excisions of confirmed Basal Cell Carcinoma (BCC) and occasionally Squamous Cell Carcinoma (SCC) occurring in areas that are clinically difficult to operate on. This includes the face, ears and neck areas and occasionally scalp region.
The procedure relies on frozen section technique, stepped levels and specimen mapping to assess the surgical margin of a specimen. Where tumour is still present at the margin, further tissue is taken and the procedure repeated until all surgical margins are free from tumour. The procedure allows for a surgical margin clearance of 0.5mm and is considered tissue sparing. This also allows for improved healing and reduced scarring in patients undergoing this procedure. Occasionally it may be necessary to fix the specimen in 10% neutral buffered formalin for processing at a later date at the laboratory. In these cases the specimen and request form must be transported to Heartlands Hospital labelled URGENT MOHS SPECIMEN.Healthy tissue is spared and recurrence is extremely rare using this technique.
Information regarding the surgery is supplied to the patient by the Dermatology Department.
MOHS Clinics run on Mondays and Wednesdays between 09:00 and 17:00.
For further information please contact the Solihull Dermatology department on 0121 424 5147
In the last 5 years requests for tumour marker tests from Primary Care have more than doubled. This high use in Primary Care is worrying because the majority of tumour markers (eg. CEA, CA19-9) are neither specific nor sensitive enough for use in the diagnosis of malignancy. See this link for a summary of the main tumour markers, their uses and limitations.
The main use for tumour markers is in monitoring disease progression, treatment or recurrence of a histologically diagnosed cancer. A recent audit of Primary Care requests for tumour markers found that only 9% of CEA and 4% of CA19-9 were requested for these reasons; the rest being for non-specific symptoms.
In contrast to the above, CA125 and PSA do have use in diagnosis of their related cancers, however it should also be noted that these are still only a diagnostic aid and should be used with caution as both can be raised in a number of other benign conditions (see table). Please click the relevant links below of links to guidelines relating to their use in Primary Care.
Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.
The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html. Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.
For further information contact Louise Fallon, Quality Manager, 0121 424 1235